BACKGROUND: Marinobufagenin (MBG), a bufadienolide cardiotonic steroid, induces cardiovascular fibrosis. Because levels of MBG in preeclampsia are increased, and anti-MBG monoclonal antibody reduces blood pressure (BP) in a rat model of preeclampsia, we hypothesized that in preeclampsia, elevated MBG levels would be associated with the development of fibrosis in feto-placental circulation and with impairment of vascular relaxation. METHOD: We studied 16 patients with preeclampsia (systolic BP=150±4 mmHg; 28±2 years, 37±1 weeks gestational age) and 14 gestational age-matched normal pregnant women (systolic BP=112±2 mmHg). RESULTS: Preeclampsia was associated with a rise in plasma and placental levels of MBG. In preeclamptic umbilical arteries, the expression of Fli-1, a transcription factor and a negative regulator of fibrosis, was significantly reduced (P<0.001), whereas procollagen-1 expression was increased (P<0.01). As compared to control vessels, isolated rings of umbilical arteries from patients with preeclampsia demonstrated unaltered responsiveness to endothelin-1 (EC50=2.2 and 3.2 nmol/l, respectively), but exhibited an impaired response to the relaxant effect of sodium nitroprusside (EC50=1.5 vs. 32.4 nmol/l, P<.001) following endothelin-1-induced constriction. Ex-vivo treatment of normal umbilical arteries explants with 1 and 10 nmol/l MBG for 24 h mimicked the effects of preeclampsia, specifically suppressed Fli-1 and increased collagen-1 expression while impairing vasorelaxation. CONCLUSION: Our results indicate that in preeclampsia, elevated levels of MBG induce vascular fibrosis via a Fli-1-dependent mechanism which leads to an impairment of vasorelaxation, and suggest that MBG represents a potential target for therapy of this syndrome.
BACKGROUND:Marinobufagenin (MBG), a bufadienolidecardiotonic steroid, induces cardiovascular fibrosis. Because levels of MBG in preeclampsia are increased, and anti-MBG monoclonal antibody reduces blood pressure (BP) in a rat model of preeclampsia, we hypothesized that in preeclampsia, elevated MBG levels would be associated with the development of fibrosis in feto-placental circulation and with impairment of vascular relaxation. METHOD: We studied 16 patients with preeclampsia (systolic BP=150±4 mmHg; 28±2 years, 37±1 weeks gestational age) and 14 gestational age-matched normal pregnant women (systolic BP=112±2 mmHg). RESULTS: Preeclampsia was associated with a rise in plasma and placental levels of MBG. In preeclamptic umbilical arteries, the expression of Fli-1, a transcription factor and a negative regulator of fibrosis, was significantly reduced (P<0.001), whereas procollagen-1 expression was increased (P<0.01). As compared to control vessels, isolated rings of umbilical arteries from patients with preeclampsia demonstrated unaltered responsiveness to endothelin-1 (EC50=2.2 and 3.2 nmol/l, respectively), but exhibited an impaired response to the relaxant effect of sodium nitroprusside (EC50=1.5 vs. 32.4 nmol/l, P<.001) following endothelin-1-induced constriction. Ex-vivo treatment of normal umbilical arteries explants with 1 and 10 nmol/l MBG for 24 h mimicked the effects of preeclampsia, specifically suppressed Fli-1 and increased collagen-1 expression while impairing vasorelaxation. CONCLUSION: Our results indicate that in preeclampsia, elevated levels of MBG induce vascular fibrosis via a Fli-1-dependent mechanism which leads to an impairment of vasorelaxation, and suggest that MBG represents a potential target for therapy of this syndrome.
Authors: Olga V Fedorova; Natalia A Dorofeeva; Denis A Lopatin; Edward G Lakatta; Alexei Y Bagrov Journal: Hypertension Date: 2002-02 Impact factor: 10.190
Authors: D A Lopatin; E K Ailamazian; R I Dmitrieva; V M Shpen; O V Fedorova; P A Doris; A Y Bagrov Journal: J Hypertens Date: 1999-08 Impact factor: 4.844
Authors: Olga V Fedorova; Andrey S Simbirtsev; Nikolai I Kolodkin; Alexander Y Kotov; Natalia I Agalakova; Vladimir A Kashkin; Natalia I Tapilskaya; Anton Bzhelyansky; Vitaly A Reznik; Elena V Frolova; Elena R Nikitina; Georgy V Budny; Dan L Longo; Edward G Lakatta; Alexei Y Bagrov Journal: J Hypertens Date: 2008-12 Impact factor: 4.844
Authors: Valentina V Ishkaraeva-Yakovleva; Olga V Fedorova; Nelly G Solodovnikova; Elena V Frolova; Anton M Bzhelyansky; Igor V Emelyanov; C David Adair; Irina E Zazerskaya; Alexei Y Bagrov Journal: Reprod Sci Date: 2012-05-30 Impact factor: 3.060
Authors: Olga V Fedorova; Valentina I Zernetkina; Victoria Y Shilova; Yulia N Grigorova; Ondrej Juhasz; Wen Wei; Courtney A Marshall; Edward G Lakatta; Alexei Y Bagrov Journal: Circ Cardiovasc Genet Date: 2015-09-15
Authors: Laura Ormesher; Suzanne Higson; Matthew Luckie; Stephen A Roberts; Heather Glossop; Andrew Trafford; Elizabeth Cottrell; Edward D Johnstone; Jenny E Myers Journal: Hypertension Date: 2020-10-05 Impact factor: 10.190
Authors: Yulia N Grigorova; Ondrej Juhasz; Valentina Zernetkina; Kenneth W Fishbein; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov Journal: Am J Hypertens Date: 2015-09-07 Impact factor: 2.689
Authors: Olga V Fedorova; Igor V Emelianov; Konstantin A Bagrov; Yulia N Grigorova; Wen Wei; Ondrej Juhasz; Elena V Frolova; Courtney A Marshall; Edward G Lakatta; Alexandra O Konradi; Alexei Y Bagrov Journal: J Hypertens Date: 2015-08 Impact factor: 4.844
Authors: Olga V Fedorova; Artem V Fadeev; Yulia N Grigorova; Courtney A Marshall; Valentina Zernetkina; Nikolai I Kolodkin; Natalia I Agalakova; Alexandra O Konradi; Edward G Lakatta; Alexei Y Bagrov Journal: J Cardiovasc Pharmacol Date: 2019-11 Impact factor: 3.105
Authors: Irina E Zazerskaya; Valentina V Ishkaraeva; Elena V Frolova; Nelly G Solodovnikova; Yulia N Grigorova; C David Adair; Olga V Fedorova; Alexei Y Bagrov Journal: Am J Hypertens Date: 2013-07-22 Impact factor: 2.689
Authors: Natalia I Agalakova; Vitaly A Reznik; Olga V Nadei; Ivan A Ershov; Olga S Rassokha; Marina L Vasyutina; Dmitry O Ivanov; C David Adair; Michael M Galagudza; Alexei Y Bagrov Journal: Am J Hypertens Date: 2020-05-21 Impact factor: 2.689